
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
Obesity is a primary risk factor for cardiovascular disease and can also be modified with comprehensive care. Test yourself on the AHA/ACC recommendations for that care.
Prevention and management of overweight and obesity is central to primary prevention of CVD. Test yourself on the most r






